| Literature DB >> 26521790 |
Xiao-Peng Qu, Zhen-Xiao Huang, Yan Sun, Ting Ye, Shun-Jiu Cui, Qian Huang, Li-Jing Ma, Qing-Wen Yang, Hong Wang, Er-Zhong Fan, Ying Li, Liang Zhang, Bing Zhou1.
Abstract
BACKGROUND: Adenoid hypertrophy (AH) is associated with pediatric chronic rhinosinusitis (pCRS), but its role in the inflammatory process of pCRS is unclear. It is thought that innate immunity gene expression is disrupted in the epithelium of patients with chronic rhinosinusitis (CRS), including antimicrobial peptides and pattern recognition receptors (PRRs). The aim of this preliminary study was to detect the expression of innate immunity genes in epithelial cells of hypertrophic adenoids with and without pCRS to better understand their role in pCRS.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26521790 PMCID: PMC4756897 DOI: 10.4103/0366-6999.168056
Source DB: PubMed Journal: Chin Med J (Engl) ISSN: 0366-6999 Impact factor: 2.628
Demographic and clinical characteristics of participants in the two groups (n = 9 in each group)
| Parameters | AH group | pCRS group | |
|---|---|---|---|
| Gender (male/female), | 5/4 | 5/4 | 1.000* |
| Age (years), mean ± SD | 7.7 ± 1.9 | 8.1 ± 3.2 | 0.554† |
| SNOT-22 score‡, mean ± SD | 11.8 ± 7.0 | 30.9 ± 18.5 | 0.011† |
| Adenoids size (grade 3/4) | 6/3 | 4/5 | 0.833* |
| Asthma (presence/absence), | 0/9 | 0/9 | 1.000* |
| SPT (positive/negative), | 0/9 | 0/9 | 1.000* |
*Determined with Fisher’s exact test; †Determined with t-test; ‡The maximum score is 110. AH: Adenoids hypertrophy; pCRS: Pediatric chronic rhinosinusitis; SNOT-22: Sino-nasal Outcome Test-22; SPT: Skin-prick test; SD: Standard deviation.
Primers used for RT-qPCR analysis
| Gene | Primer sequences, 5’–3’ | Amplicon size (bp) |
|---|---|---|
| HBD-2 | For: TCTTCATATTCCTGATGCCTCTTCC | 133 |
| Rev: AGACCACAGGTGCCAATTTGTTTAT | ||
| HBD-3 | For: TCTTCTGTTTGCTTTGCTCTTCCTG | 100 |
| Rev: GCCGCCTCTGACTCTGCAATAATAT | ||
| SP-A | For: TCTGCCCCAAAACTAAAACACTCTT | 217 |
| Rev: TAGGCTGGGAGTCAGGAAATCTTGT | ||
| SP-D | For: GTGTCGGGGAGAAGATTTTCAAGA | 216 |
| Rev: ACTCTCCTGTGGGGTAGGTGAAC | ||
| TLR 1 | For: CAGCTTTAGCAGCCTTTCTGTATTG | 107 |
| Rev: CCCCTGCTTTTATTGACCTCATCTT | ||
| TLR 2 | For: TCTGGCATGTGCTGTGCTCTGTT | 131 |
| Rev: GGAGCTTTCCTGGGCTTCCTTTT | ||
| TLR 3 | For: TTAGCACGGCTCTGGAAACACG | 281 |
| Rev: TGTGGAGGTGAGACAGACCCTTTAG | ||
| TLR 4 | For: TGCAATGGATCAAGGACCAGAGG | 149 |
| Rev: ACTGAGGACCGACACACCAATGAT | ||
| TLR 5 | For: TCAAAATCGCTTCTCCTCCTGTAGT | 193 |
| Rev: TCCTGGTGGAAGGGAATTAAGATAG | ||
| TLR 6 | For: GTTATAGAGGAAGCCCACTAAAGGAC | 109 |
| Rev: ACAGTCACAGCCAACACCAGCA | ||
| TLR 7 | For: GCATTTTACTTGTCCCATCAGAGGC | 137 |
| Rev: CACTCAAGGACAGAACTCCCACAG | ||
| TLR 8 | For: GACACCAAAGATGCCTCTGTTACTG | 73 |
| Rev: TGTCTCGGCTCTCTTCAAGGTGGTA | ||
| TLR 9 | For: GCATCACCTCTGTGGCTGGGACCTCT | 110 |
| Rev: CATCGTAGGGCAGGGCATCCTCATCT | ||
| TLR 10 | For: AAAACAACCCAAGAACAACTCAAGA | 142 |
| Rev: CATAAAGGCAAATCAAGATAGAACCAT | ||
| NOD1 | For: CCAGCAGTCCTATGAGTTTTTCCAC | 245 |
| Rev: AGAGGTTGGTGAACTGGAAGTGATC | ||
| NOD2 | For: AGCCTCCGCAAGCACTTCCACT | 213 |
| Rev: AAAGGCCAGGGCAGCACACTCA | ||
| NALP 3 | For: TCCTGGCTGTAACATTCGGAGATT | 90 |
| Rev: TTGCTGCTGAGGACCAAGGAGAT | ||
| RIG-1 | For: AACCTGGCATATTGACTGGACGT | 192 |
| Rev: CATTGCCCACATACTCATAAAGGAT | ||
| MDA-5 | For: AAGTAGGAGTCAAAGCCCACCATCT | 196 |
| Rev: GTGACGAGACCATAACGGATAACAA | ||
| NF-κB | For: GGGGACTACGACCTGAATG | 118 |
| p65 | Rev: GGGCACGATTGTCAAAGAT | |
| β-actin | For: ACTTAGTTGCGTTACACCCTT | 156 |
| Rev: GTCACCTTCACCGTTCCA |
HBD: Human β-defensins; SP: Surfactant protein; TLR: Toll-like receptors; NOD: Nucleotide-binding oligomerization domain; NALP 3: NACHT, LRR, and PYD domains-containing protein 3; RIG-1: Retinoic acid-induced gene 1; MDA-5: Melanoma differentiation-associated gene 5; NF-κB: Nuclear factor-κB; RT-qPCR: Real-time quantitative polymerase chain reaction; For: forward; Rev: reverse.
Relative expression levels of PRRs and AMPs in isolated adenoidal epithelium of the two groups (n = 9 in each group)
| Gene | AH group | pCRS group | |
|---|---|---|---|
| TLR 1 | 2.60 ± 0.59 | 4.40 ± 1.32 | 0.232 |
| TLR 2 | 4.41 (3.65, 8.37) | 3.70 (2.22, 9.23) | 0.453* |
| TLR 3 | 3.36 (2.70, 3.63) | 3.01 (1.44, 4.43) | 0.691* |
| TLR 4 | 0.84 (0.40, 1.13) | 1.34 (0.37, 1.81) | 0.171* |
| TLR 5 | 4.57 (2.06, 5.53) | 4.92 (2.24, 8.28) | 0.566* |
| TLR 6 | 5.23 (2.92, 6.63) | 4.00 (2.76, 6.22) | 0.895* |
| TLR 7 | 3.31 (1.09, 4.83) | 3.64 (0.61,6.29) | 0.825* |
| TLR 8 | 6.10 (0.59, 14.78) | 6.14 (1.57, 11.55) | 0.895* |
| TLR 9 | 1.69 (1.04, 2.77) | 1.66 (1.22, 2.71) | 0.895* |
| TLR 10 | 1.00 (0.45, 1.68) | 0.69 (0.36, 1.85) | 0.965* |
| NOD 1 | 0.26 (0.10, 0.63) | 0.21 (0.09, 0.68) | 0.965* |
| NOD 2 | 4.61 (2.57, 5.70) | 4.64 (2.36, 5.66) | 0.895* |
| NALP 3 | 2.58 (1.53, 9.00) | 2.10 (1.34, 7.12) | 0.627* |
| RIG-1 | 1.48 ± 0.31 | 1.28 ± 0.19 | 0.600 |
| MDA-5 | 2.02 (1.46, 2.74) | 1.48 (1.05, 3.55) | 0.508* |
| NF-κB | 0.85 ± 0.06 | 0.80 ± 0.06 | 0.588 |
| HBD-2 | 38.71 (11.01, 60.15) | 26.90 (0.72, 44.48) | 0.354* |
| HBD-3 | 1.20 (0.12, 3.20) | 1.09 (0.19, 3.13) | 0.965* |
| SP-A | 1.97 (0.84, 14.42) | 1.79 (0.98, 5.30) | 0.508* |
| SP-D | 1.21 ± 0.15 | 0.73 ± 0.10 | 0.017† |
*Mann-Whitney U-test was used for the comparison; †Statistically significant (P < 0.05). Normally distributed data are presented as the mean ± SD, nonnormally distributed data are presented as median (P25, P75). HBD: Human β-defensins; SP: Surfactant protein; TLR: Toll-like receptors; NOD: Nucleotide-binding oligomerization domain; NALP 3: NACHT, LRR, and PYD domains-containing protein 3; RIG-1: Retinoic acid-induced gene 1; MDA-5: Melanoma differentiation-associated gene 5; NF-κB: Nuclear factor-κB; pCRS: Pediatric chronic rhinosinusitis; PRRs: Pattern recognition receptors; AMPs: Antimicrobial peptides; SD: Standard deviation; AH: Adenoids hypertrophy.